Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting

被引:39
作者
Iancu, Emanuela M. [1 ]
Kandalaft, Lana E. [1 ,2 ]
机构
[1] CHU Vaudois, Ctr Expt Therapeut, Dept Oncol, CH-1011 Lausanne, Switzerland
[2] Univ Lausanne, Ludwig Inst Canc Res, Dept Oncol, CH-1011 Lausanne, Switzerland
关键词
MEDICINAL PRODUCTS; GMP FACILITY;
D O I
10.1016/j.copbio.2020.05.005
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Academic medicine serves to advance the scientific field and provide the highest quality of clinical care. This applies to cancer where there is a continuous unmet need for innovation. In the last decade, we have observed a significant development of commercial cell and gene-therapy products with a rapid growth of the industry. Hospital-based Good Manufacturing Practice (GMP) facilities which support primarily investigator -initiated clinical trials, are increasingly involved in interactions with industry. Although the missions of academic and commercial GMP facilities are different, both are bound by industry standards and often engage in technology transfer with industry partners. The successful set-up of an academic GMP facility requires striking a unique balance between commercial and academic priorities. Here we review the role of academic facilities in the development of cellular therapies with a focus on cancer immunotherapy and we highlight some of the most challenging operational aspects and point to potential solutions.
引用
收藏
页码:233 / 241
页数:9
相关论文
共 15 条
[1]   Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs [J].
Abou-El-Enein, Mohamed ;
Roemhild, Andy ;
Kaiser, Daniel ;
Beier, Carola ;
Bauer, Gerhard ;
Volk, Hans-Dieter ;
Reinke, Petra .
CYTOTHERAPY, 2013, 15 (03) :362-383
[2]   Considering Cell Therapy Product "Good Manufacturing Practice" Status [J].
Bedford, Patrick ;
Jy, Juliana ;
Collins, Lucas ;
Keizer, Steven .
FRONTIERS IN MEDICINE, 2018, 5
[3]   Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation [J].
de Wilde, Sofieke ;
Veltrop-Duits, Louise ;
Hoozemans-Strik, Merel ;
Ras, Thirza ;
Blom-Veenman, Janine ;
Guchelaar, Henk-Jan ;
Zandvliet, Maarten ;
Meij, Pauline .
CYTOTHERAPY, 2016, 18 (06) :797-805
[4]   Proceedings of the first academic symposium on developing, qualifying and operating a cell and gene therapy manufacturing facility [J].
Digiusto, David L. ;
Melsop, Kathryn ;
Srivastava, Rashi ;
Tran, Chy-Anh T. .
CYTOTHERAPY, 2018, 20 (12) :1486-1494
[5]  
Elverum K., 2019, GENE THER
[6]   Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma [J].
Garfall, Alfred L. ;
Maus, Marcela V. ;
Hwang, Wei-Ting ;
Lacey, Simon F. ;
Mahnke, Yolanda D. ;
Melenhorst, J. Joseph ;
Zheng, Zhaohui ;
Vogl, Dan T. ;
Cohen, Adam D. ;
Weiss, Brendan M. ;
Dengel, Karen ;
Kerr, Naseem D. S. ;
Bagg, Adam ;
Levine, Bruce L. ;
June, Carl H. ;
Stadtmauer, Edward A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (11) :1040-1047
[7]   GMP CAR-T cell production [J].
Gee, Adrian P. .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (02) :126-134
[8]  
Greenberg-Worisek AJ, 2018, TISSUE ENG PART B-RE, V24, P493, DOI [10.1089/ten.teb.2018.0114, 10.1089/ten.TEB.2018.0114]
[9]   Towards a commercial process for the manufacture of genetically modified T cells for therapy [J].
Kaiser, A. D. ;
Assenmacher, M. ;
Schroeder, B. ;
Meyer, M. ;
Orentas, R. ;
Bethke, U. ;
Dropulic, B. .
CANCER GENE THERAPY, 2015, 22 (02) :72-78
[10]   Building blocks for institutional preparation of CTL019 delivery [J].
McGuirk, Joseph ;
Waller, Edmund K. ;
Qayed, Muna ;
Abhyankar, Sunil ;
Ericson, Solveig ;
Holman, Peter ;
Keir, Christopher ;
Myers, G. Douglas .
CYTOTHERAPY, 2017, 19 (09) :1015-1024